Pancreatic Cancer Therapy Market Growth and Recent Trends by 2025

[Research Report] The pancreatic cancer therapy market is expected to reach US$ 4056.4 million by 2025 from US$ 2011.2 million in 2017; it is estimated to grow at a CAGR of 8.1% from 2018 to 2025.

Published Report - Pancreatic Cancer Therapy Market: Strategic Insights

Market Insights

Rise in Number of Patients Suffering with Pancreatic Cancer

Pancreatic cancer is one of the aggressive cancers that originate in the tissues of the pancreas and rapidly spreads to the nearby organs. Pancreatic cancer is the 12th most commonly occurring cancer in the world. According to the American Cancer Society, ~55,440 patients in the US are expected to be diagnosed with pancreatic cancer in 2018. Moreover, the ACS also reports that pancreatic cancer is the third leading cause of death related to cancer in the US and is expected to be the second leading cause of death by 2020. According to Cancer Research UK, approximately 9,921 new cases of pancreatic cancer were diagnosed in the UK in 2015, while 8,912 patients died due to same cancer. The cancer is almost always fatal and thus demands potential therapies for the patients’ treatment. For instance, the American Cancer Society suggests that pancreatic cancer accounts for approximately 3% of deaths of all cancers in the US. According to the National Institute of Health, an estimated of 68,615 patients in 2015 were living with pancreatic cancer in the US. The increasing incidence and prevalence of pancreatic cancer are expected to increase the demand for drugs, therapies, and treatment of patients. Moreover, the rising number of patients results in advancements in molecular biology and chemical drug formulation. Thus, a huge pool of patients who have pancreatic cancer is expected to increase the growth of the global pancreatic cancer therapy market over the forecast years.

Type Insights

Based on type, the pancreatic cancer therapy market is segmented into endocrine pancreatic cancer and exocrine pancreatic cancer. In 2017, the exocrine pancreatic cancer segment held the largest share of the market, by type. The exocrine pancreatic cancer segment is expected to grow at the fastest rate during the coming years as this type of cancer is the most common and majorly occurring type and thus is expected to have massive patient pool over the forecast years.

Therapy Insights

Based on therapy, the pancreatic cancer therapy market is segmented into biologic therapy, chemotherapy, and others. In 2017, biologic therapy segment held the largest share of the market, by therapy. Moreover, the biologic therapy segment is expected to grow at the fastest rate during the coming years owing to increasing number of novel upcoming immunotherapies as well as targeted cell therapy that treats the cancer without any severe side effects and has number of therapeutic benefits over the conventional chemotherapies.

Organic strategies are the more commonly adopted strategies by companies in the pancreatic cancer therpay market, which enables them expand their global footprints, and product and service portfolios. The market players have also adopted organic strategies such as product approvals, clinical trials and others strategies have enabled them to enlarge their global customer base, which also permits them to maintain their brand name globally.

Pancreatic Cancer Therapy

Published Report - Pancreatic Cancer Therapy Market Players Density: Understanding Its Impact on Business Dynamics

The Published Report - Pancreatic Cancer Therapy Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

Global Pancreatic Cancer Therapy Market – By Type

• Exocrine Pancreatic Cancer
• Endocrine Pancreatic Cancer

Global Pancreatic Cancer Therapy Market– By Therapy

• Biologics Therapy
• Chemotherapy
• Others

Global Pancreatic Cancer Therapy Market– By Geography

• North America
  • US
  • Canada
  • Mexico
• Europe
  • France
  • Germany
  • Italy
  • UK
  • Spain
• Asia Pacific (APAC)
  • China
  • India
  • South Korea
  • Japan
  • Australia
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
• South and Central America
  • Brazil
  • Argentina

Company Profiles

• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd
• Amgen Inc
• Novartis AG
• Celgene Corporation
• Merck & Co., Inc
• Pharmacyte Biotech Inc
• Clovis Oncology
• Teva Pharmaceutical Industries Ltd
• Pfizer Inc